~~<i id='42F40A62D8'><strike id='42F40A62D8'><tt id='42F40A62D8'><pre id='42F40A62D8'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

author：comprehensive 2025-09-29 21:25:41 - browse：6

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： FDA advisers vote against ALS treatment from BrainStorm

focus

leisure time

hotspot

focus

hotspot

PicturesofSenatorDianneFeinsteinrestbyacondolencebookatCityHallinSanFranciscoonFriday.BenjaminFanjoy

WSS

Lung cancer screening guidelines updated for cigarette smokers

Kidney transplant patients stopped immunosuppressants in trial

Ionis has late

Health tech startups drop sharply from 2021 highs

Kaiser Permanente unions announce official strike date

How one patient went off dialysis — and others can too

entertainment

entertainment

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

Inari Medical to buy amputation prevention company LimFlow

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

FDA advisers vote against ALS treatment from BrainStorm

United colonoscopy coverage change 'may cost lives,' doctors say

FDA advisers vote against ALS treatment from BrainStorm

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Menendez indictment could see pharma lose a key ally

Medical records are filled with copy

After Sarepta trial failure, Duchenne families brace for more debate

leisure time

Intercept Pharmaceuticals sells itself for less than $1 billion

Covid vaccines: Private market messier than government rollout

DeepMind touts AlphaFold's new skills as protein folding AI models face off

After Sarepta trial failure, Duchenne families brace for more debate

Did you have Obamacare on your GOP debate bingo card?

Brain injuries and the importance of a second opinion

hotspot

focus

hotspot

hotspot